LENZ vs. CDTX, ENTX, ALGS, AVRO, IKNA, TSBX, DTIL, ELUT, GNTA, and TIL
Should you be buying LENZ Therapeutics stock or one of its competitors? The main competitors of LENZ Therapeutics include Cidara Therapeutics (CDTX), Entera Bio (ENTX), Aligos Therapeutics (ALGS), AVROBIO (AVRO), Ikena Oncology (IKNA), Turnstone Biologics (TSBX), Precision BioSciences (DTIL), Elutia (ELUT), Genenta Science (GNTA), and Instil Bio (TIL). These companies are all part of the "biological products, except diagnostic" industry.
Cidara Therapeutics (NASDAQ:CDTX) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, community ranking, dividends and institutional ownership.
LENZ Therapeutics has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -33.19%. Cidara Therapeutics' return on equity of -33.12% beat LENZ Therapeutics' return on equity.
35.8% of Cidara Therapeutics shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 7.4% of Cidara Therapeutics shares are owned by insiders. Comparatively, 38.4% of LENZ Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Cidara Therapeutics has higher revenue and earnings than LENZ Therapeutics. Cidara Therapeutics is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cidara Therapeutics has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.2, suggesting that its stock price is 80% less volatile than the S&P 500.
Cidara Therapeutics received 433 more outperform votes than LENZ Therapeutics when rated by MarketBeat users. However, 100.00% of users gave LENZ Therapeutics an outperform vote while only 70.19% of users gave Cidara Therapeutics an outperform vote.
Cidara Therapeutics presently has a consensus target price of $71.25, indicating a potential upside of 494.74%. LENZ Therapeutics has a consensus target price of $31.33, indicating a potential upside of 97.44%. Given LENZ Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Cidara Therapeutics is more favorable than LENZ Therapeutics.
In the previous week, Cidara Therapeutics had 31 more articles in the media than LENZ Therapeutics. MarketBeat recorded 31 mentions for Cidara Therapeutics and 0 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 0.27 beat Cidara Therapeutics' score of 0.00 indicating that Cidara Therapeutics is being referred to more favorably in the media.
Summary
Cidara Therapeutics beats LENZ Therapeutics on 10 of the 18 factors compared between the two stocks.
Get LENZ Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LENZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LENZ Therapeutics Competitors List
Related Companies and Tools
